Rapport Therapeutics, Inc. Common StockRAPPNASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P33
Within normal range
vs 2Y Ago
0.3x
Contraction
Streak
2 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 55.56% |
| 2024 | 117.63% |
| 2023 | 207.17% |
| 2022 | 0.00% |